Spruce Biosciences, Inc.
NASDAQ:SPRBBiotechnology
+$2.47 today
- Market cap
- $117.37M
- Beta
- 3.20
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$27.11
Volume 0.06M
Average 0.06M
SPRB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Spruce Biosciences, Inc.NASDAQ: SPRB
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $7.58M fell 30.1% year over year, ahead of the -64.4% change in trailing-twelve-month research & development. Sequentially, it rose 84.6% from the prior quarter. Over 3 fiscal years it compounded at -17.8% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -30.1% holds above the trailing-twelve-month pace of -64.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 19.52M USD
- Year-over-year change
- -57.9%
- 4-year CAGR
- -10.7%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.52M | -57.9% |
| FY2024 | 2024-12-31 | 46.42M | -6.1% |
| FY2023 | 2023-12-31 | 49.43M | +40.4% |
| FY2022 | 2022-12-31 | 35.2M | +14.7% |
| FY2021 | 2021-12-31 | 30.7M | — |
Research & Development vs competitors
How SPRB compares with its peers on the latest reported figures
- SPRB's LTM Mar 2026 research & development of $16.69M is the 6th highest of the 9 companies compared; the peer median is $22.63M.
- Its year-over-year change of -64.4% is the 8th highest of 9, against a peer median of -15.8%.
- Over three fiscal years its annual growth of -17.8% compares with a peer median of +6.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $16.37B | +432309.4% | +1606.6% | — |
| LTM Mar 2026 | $36.03M | +4.0% | -0.7% | 110.1% | |
| LTM Jun 2026 | $32.91M | -39.6% | -5.9% | 156.7% | |
| LTM Mar 2026 | $24.01M | +104.7% | +13.1% | 65.2% | |
| LTM Mar 2026 | $21.25M | -43.8% | +8527.1% | 6378.2% | |
| LTM Mar 2026 | $16.69M | -64.4% | -17.8% | — | |
| LTM Mar 2026 | $9.91M | -70.5% | -30.1% | — | |
| LTM Mar 2026 | $4.28M | -18.5% | -39.5% | 186.8% | |
| LTM Mar 2026 | $1.43M | -13.1% | +294.0% | 100.9% | |
| Peer median (excluding SPRB) | $22.63M | -15.8% | +6.2% | 133.4% | |
Competitors are the stored peer set for SPRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 10.09M | 4.91M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 10.09M | 4.91M | 0 |
| Gross Margin | — | — | 100.0% | 100.0% | — |
| Research & Development | 30.7M | 35.2M | 49.43M | 46.42M | 19.52M |
| Selling, General & Admin | 11.37M | 12.09M | 12.65M | 14.64M | 16.99M |
| Operating Expenses | 42.07M | 47.28M | 62.08M | 61.06M | 36.51M |
| Depreciation & Amortization | 68K | 74K | 70K | 46K | 21K |
| EBITDA | (41.88M) | (45.69M) | (47.37M) | (52.68M) | (38.86M) |
| EBITDA Margin | — | — | -469.5% | -1072.8% | — |
| Operating Income | (42.07M) | (47.28M) | (51.99M) | (56.15M) | (36.51M) |
| Operating Margin | — | — | -515.3% | -1143.4% | — |
| Interest Income | 119K | 1.52M | 4.56M | 3.42M | 1.14M |
| Interest Expense | 345K | 420K | 483K | 307K | 90K |
| Other Income / Expenses | (226K) | 1.1M | 4.07M | 3.12M | (2.45M) |
| Income Before Tax | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Pre-Tax Margin | — | — | -475.0% | -1079.9% | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (42.29M) | (46.18M) | (47.92M) | (53.04M) | (38.97M) |
| Net Margin | — | — | -475.0% | -1079.9% | — |
| EPS (Basic) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| EPS (Diluted) | (68.25) | (72.00) | (93.00) | (96.75) | (50.83) |
| Weighted Avg Shares | 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
| Weighted Avg Shares (Diluted) | 607.4K | 611.71K | 500.63K | 536.44K | 766.6K |
Spruce Biosciences, Inc.
NASDAQ:SPRB
Intrinsic Alpha fair value
Locked
Current Price
$40.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.